Boston Scientific EP Segment Sales Miss
Analysis based on 10 articles · First reported Feb 05, 2026 · Last updated Feb 23, 2026
The market reacted negatively to Boston Scientific's Q4 2025 earnings miss, particularly in its electrophysiology segment, causing a significant drop in its stock price. This event highlights the sensitivity of investor confidence to growth projections and actual performance in key market segments.
Boston Scientific Corporation reported its fourth-quarter 2025 results, exceeding analyst expectations for overall earnings per share and total revenue. However, its electrophysiology (EP) segment, which was positioned as a primary growth engine, reported sales of $890 million, falling approximately $43 million below the $933 million consensus estimate. This shortfall, coupled with management's revised growth outlook for the EP segment (approximately 15% vs. market expectation of 25%), led to a 17.5% decline in Boston Scientific's shares, reaching a 52-week low. Following these developments, Levi & Korsinsky initiated an investigation into Boston Scientific for potential violations of federal securities laws.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard